A Study of TLN-254 in Participants With Relapsed or Refractory T-cell Lymphoma
Phase 1
50
about 3.9 years
18+
4 sites in CA, MO, NY +1
Why this study is shown
What this study is about
Researchers are testing a treatment called TLN-254 for people with relapsed or refractory T-cell lymphoma. The trial will last about 1430 days and aims to see if TLN-254 can fight the cancer.
Simplified from trial records by PatientMatch.
What you may be asked to do
- 1.Take TLN-254
Participation Burden
What's physically and logistically required of participants.
Requires travel to a study site
How treatment is administered
You are randomly assigned, but you will know your treatment.
Extracted study details
Pulled from the trial record to show what is being tested and what the study is measuring.
Primary: Percentage of Participants With CR, Percentage of Participants With Objective Response, Percentage of Participants With PR
Secondary: Duration of Response (DOR), Number of Participants With Severity of TEAEs Based on National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE) Version 5.0, Number of Participants With Treatment-Emergent Adverse Events (TEAEs) and Serious Adverse Events (SAEs)
Oncology